Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients

Name: Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients
Published: 2019
License: Public Domain

Yonsei University · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

gastric-cancer

gastric cancer, egfr/her2 co-expressing gastric cancer, varlitinib, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients

Related documents